Abstract: New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects of the structural formula ##STR1## and therapeutically acceptable salts thereof, in which formula R is selected from the group consisting of --C(CH.sub.3).sub.3, ##STR2## R.sup.1 is selected from the group consisting of H and R.sup.2, R.sup.2 represents the radical of the formula ##STR3## wherein R.sup.3 is selected from the group consisting of (a) H(b) alkyl groups containing 1-3 carbon atoms ##STR4## wherein R.sup.5 is selected from the group consisting of (e) OH(b) alkoxy groups containing 1-3 carbon atoms and whereinR.sup.4 is selected from the group consisting of(a) H(b) alkyl groups containing 1-3 carbon atoms, with the proviso that R.sup.3 and R.sup.4 are combined as follows:______________________________________ when R.sup.3 is then is R.sup.

Abstract: The invention refers to compounds having anti-inflammatory activity, characterized by the formula ##STR1## in the form of a stereoisomeric mixture or an epimer of the R or S type regarding the orientation of the substituents at the carbon atom in position 22, in which formula A is n-propyl or n-butyl and Z is hydroxyl or hydroxyl esterified with a fatty acid with a straight or branched hydrocarbon chain having 1-5 carbon atoms.The invention also refers to a process for the preparation of these compounds, a pharmaceutical preparation containing one of the compounds and a method for the treatment and control of inflammatory conditions.

Abstract: A pharmaceutical steroid composition for topical application producing a minimum of skin irritating effects. The composition comprises a corticosteroid in a multiple emulsion vehicle.A process for the preparation of the composition.

Abstract: A method for the treatment of chronic obstructive airway disease or cardiac disease by administration 3-ethylxantine or a pharmaceutically acceptable salt thereof; a pharmaceutical preparation containing 3-ethylxanthine.

Abstract: A method for the treatment of chronic obstructive airway disease or cardiac disease, characterized by the administration of a compound of the formula ##STR1## wherein R is n-propyl, n-butyl or isobutyl or a therapeutically acceptable salt thereof.

Abstract: An aerosol inhalation device comprising an elongated chamber, an outer chamber part of which has an outlet opening and is telescopically displaceable over an inner chamber part which is connectable to an aerosol dispenser and provided with a flexible tongue which on telescoping the device together closes the outlet opening.

Abstract: A pharmaceutical composition containing zinc in the form of one or more water soluble zinc salts and a complex-former selected from the group consisting of hydroxycarboxylic acids, acid anhydrides, or salts thereof. The water solutions thereof give a palatable, acceptable peroral zinc solution and are useful for treating leg ulcers, post-operative wounds, decubital ulcers and other diseased conditions in zinc anemia.

Abstract: An FM tuner control circuit contains a digital frequency synthesizing control circuit, digital computer means including a microprocessor, a memory circuit, and a manual control circuit for digitally tuning the tuner to any desired FM station. The memory circuit includes a read-only memory containing programs for the microprocessor and a random-access memory in which a group of predetermined station frequencies can be stored. The control circuit also includes a call letter display circuit, a frequency scale pointer display circuit, a frequency display circuit, a manual tuning circuit, and remote control switches for the manual control circuit.

Abstract: Compounds of the formula ##STR1## or physiologically acceptable salts thereof in which formula R.sup.1 is methyl, ethyl or n-propyl, R.sup.2 is methyl or n-propyl and R.sup.3 is ##STR2## methods for the preparation thereof; intermediates useful for their preparation; pharmaceutical preparations containing at least one of these compounds; and the use thereof in the treatment of allergy and bronchial asthma.

Abstract: A method for treating mucocutaneous herpes simplex infections in man or other animals susceptible to said infections comprising the administration of an amount of zinc in the form of a salt or a hydroxycarboxylic acid or aminocarboxylic acid complex thereof, therapeutically effective in the treatment of said infections.

Abstract: A device for use with a medicinal inhalation device comprises a rotationally symmetrical chamber having an opening to be connected to a spray nozzle and a mouthpiece. The chamber diverges conically from the opening and converges towards the mouthpiece. During passage through the chamber, an aerosol mist will lose propellant by evaporation, and smaller particles will be generated which can more readily follow the path of inhalation.

Abstract: An aerosol inhalation device is designed to use a capsule having a single dose of medication and a propellant. The device includes a hollow needle which perforates the capsule to release the medication. The capsules used with the device include a single dose of medication and an appropriate quantity of propellant.

Abstract: An FM tuner control circuit contains a digital frequency synthesizing control circuit, digital computer means including a microprocessor, a memory circuit, and a manual control circuit for digitally tuning the tuner to any desired FM station. The memory circuit includes a read-only memory containing programs for the microprocessor and a random-access memory in which a group of predetermined station frequencies can be stored. The control circuit also includes a call letter display circuit, a frequency scale pointer display circuit, a frequency display circuit, a manual tuning circuit, and remote control switches for the manual control circuit.

Abstract: An aerosol inhalation device for dispensing medicine makes use of separate propellant and medicine containers. A valve is provided, which acts in conjunction with a metering chamber, to supply a measured amount of propellant upon each activation of the device.

Abstract: Novel compounds are disclosed having useful activity as bronchodilators of improved longevity of action and reduced incidence of side effects. These compounds are described by the formula: ##STR1## wherein R.sub.1 is a member of the class consisting of tertiary butyl and cyclobutyl, and R.sub.2 is a hydrogen or 2 to 5 carbon atom acyl radical, and pharmaceutically acceptable salts thereof. The activity of these compounds is compared to previously known bronchodilators such as 1-(3', 5'-dihydroxyphenyl)-2-(isopropylamino)-ethanol, having the common name orciprenaline, and 1-(3', 4'-dihydroxyphenyl-2-isopropylamino-ethanol, having the common name isoprenaline.

Abstract: Novel compounds are disclosed having useful activity as bronchodilators of improved longevity of action and reduced incidence of side effects. These compounds are described by the formula: ##EQU1## wherein R.sub.1 is a member of the class consisting of tertiary butyl and cyclobutyl, and R.sub.2 is a hydrogen or 2 to 5 carbon atom acyl radical, and pharmaceutically acceptable salts thereof. The activity of these compounds is compared to previously known bronchodilators such as 1-(3', 5'-dihydroxyphenyl)-2-(isopropylamino)-ethanol, having the common name orciprenaline, and 1-(3', 4'-dihydroxyphenyl-2-isoproplyamino-ethanol, having the common name isoprenaline.